Navigating Next-Generation Therapies for the Management of Acid-Related Disorders

Program Description

Gastric acid-related disorders encompass a wide variety of diseases, which affect the upper gastrointestinal tract. They are caused by acid secretion imbalances, leading to the overexcretion of acid. Traditionally, proton pump inhibitors (PPIs) and histamine type-2 receptor antagonists are first line in pharmacologic therapy for the regulation of acid secretion, along with changes in diet. Often, these therapies do not fully resolve symptoms and patient adherence is poor; these factors contribute to low rates of symptom relief and poor healing. In addition, long-term safety of these agents is of concern, especially with chronic PPI use. This activity will explore the current treatment landscape, unmet needs in the management of gastroesophageal reflux disease (GERD), and the novel class of drugs called potassium-competitive acid blockers, including their mechanism of action, efficacy, safety, and their evolving role in therapy. With a greater arsenal of agents to treat the multitude of gastric acid-related disorders, pharmacists will be better able to optimize and individualize therapy for patients with GERD.

Target audience: Managed care and specialty pharmacists
Type of activity: Application
Release date: May 22, 2024
Expiration date: May 22, 2025
Learner level: Foundational
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the disease burden associated with acid-related disorders, related complications, and current unmet needs in the treatment landscape
• Compare the dosing and administration, safety and efficacy data, and mechanism of action of currently available proton pump inhibitor therapies and novel and emerging potassium-competitive acid blockers (PCABs) in the treatment of acid-related disorders
• Explore counseling strategies on the use of PCABs in acid-related disorders to optimize adherence, administration, and ensure patient access to these novel therapies

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-146-H01-P. The activity is available for CE credit through May 22, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Erin Hamai Tom, PharmD, APh, MBA, BCACP, CSP, has the following relevant financial relationship with a commercial interest to disclose:
Speakers Bureau: Janssen (Speaker for Stelara Access)

Brian A. Hemstreet, PharmD, FCCP, BCPS, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms